TITLE

Febrile neutropenia: transition towards a risk-directed approach

AUTHOR(S)
Anoop, P.; Anjay, M. A.
PUB. DATE
May 2007
SOURCE
Archives of Disease in Childhood;May2007, Vol. 92 Issue 5, p467
SOURCE TYPE
Academic Journal
DOC. TYPE
Letter
ABSTRACT
A letter to the editor is presented in response to an article about febrile neutropenia.
ACCESSION #
25374029

 

Related Articles

  • FEBRILE NEUTROPENIA. Przybylo, Michael A.; Guleri, Achyut; Sharma, Rashmi; Palmer, Ruth // BMJ: British Medical Journal (Overseas & Retired Doctors Edition;1/29/2011, Vol. 342 Issue 7791, p243 

    A letter to the editor about febrile neutropenia is presented.

  • Empirical Antifungal Therapy in Febrile Neutropenic Patients: Caution about Composite End Points and the Perils of P Values. Powers, John H.; Wingard, John R. // Clinical Infectious Diseases;12/1/2004, Vol. 39 Issue 11, p1738 

    Presents letters to the editor. Debate on clinical trials of empirical antifungal therapy in febrile neutropenic patients; Insight into the issue of invasive fungal infection.

  • HEMOPTYSIS IN PATIENT WITH FEBRILE NEUTROPENIA AND EARLY T-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA. Bertelli, Enrica; Micalizzi, Concetta; Castagnola, Elio // Euromediterranean Biomedical Journal;2016, Vol. 11, p107 

    A 16-year-old girl had been undergoing intensive chemotherapy (ALL 2009) for Early T -cell precursor acute lymphoblastic leukemia (ETP). At 22:00 of the 26th day of induction phase IA, she was found to have developed febrile neutropenia. After blood cultures were obtained, empirical therapy with...

  • Efficacy and Tolerability of Extended-Interval Aminoglycoside Administration in Pediatric Patients. Kraus, D.M.; Pai, M.P.; Rodvold, K.A. // Pediatric Drugs;2002, Vol. 4 Issue 7, p469 

    Aminoglycosides are commonly used to treat serious Gram-negative infections in pediatric patients. An effort to improve the efficacy and tolerability of this antibiotic class has led to evaluation of extended-interval aminoglycoside administration (EIAA). EIAA is designed to achieve higher peak...

  • Cytarabine/etoposide/mitoxantrone.  // Reactions Weekly;8/13/2011, Issue 1364, p16 

    The article describes the cases of two patients who developed febrile neutropenia and bacteraemia after receiving either cytarabine, etoposide or mitoxantrone.

  • Cyclophosphamide/docetaxel.  // Reactions Weekly;10/1/2011, Issue 1371, p14 

    The article describes the case of two patients who developed febrile neutropenia and exanthema after taking cyclophosphamide and docetaxel.

  • Carboplatin/cisplatin/paclitaxel.  // Reactions Weekly;8/13/2011, Issue 1364, p12 

    The article describes the case of a man who developed febrile neutropenia, diarrhoea, Campylobacter infection and neuropathic symptoms while receiving carboplatin, cisplatin and paclitaxel.

  • Fenofibrate/mycophenolate mofetil interaction.  // Reactions Weekly;1/5/2013, Issue 1433, p21 

    The article describes the case of a 57-year-old man who developed febrile neutropenia while receiving mycophenolate mofetil and fenofibrate.

  • Antineoplastics/cefepime.  // Reactions Weekly;10/15/2011, Issue 1373, p8 

    The article describes the case of a 74-year-old man with metastatic colon cancer who developed febrile neutropenia while undergoing antineoplastic and cefepime therapy.

Share

Read the Article

Other Topics